Dan L. Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza MS:BCM305, Houston, TX 77030, USA; Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza MS:BCM305, Houston, TX 77030, USA.
Cancer Epidemiol. 2013 Dec;37(6):908-12. doi: 10.1016/j.canep.2013.08.004. Epub 2013 Aug 30.
An inverse association between personal history of allergies/asthma and glioma risk has been fairly consistently reported in the epidemiologic literature. However, the role of regular antihistamine use remains controversial due to a small number of studies reporting contradictory findings. We evaluated the association between regular use of oral antihistamines and glioma risk, adjusting for a number of relevant factors (e.g., immunoglobulin E levels and history of chickenpox).
We used a subset of the Harris County Case-Control Study, which included 362 pathologically confirmed glioma cases and 462 cancer-free controls, to evaluate this association using unconditional multivariable logistic regression. These models were run among the overall study population and stratified by allergy status. Cox regression was utilized to examine whether antihistamine use was associated with mortality among all cases and separately among high-grade cases.
Antihistamine use was strongly associated with glioma risk among those with a positive allergy/asthma history (OR: 4.19, 95% CI: 2.06-8.51), but not among those with a negative history (OR: 1.59, 95% CI: 0.95-2.67). There were no significant associations between antihistamine use and survival among cases.
The current study implies that regular antihistamine use may increase glioma risk. However, several larger studies are necessary before definitive conclusions can be drawn.
过敏/哮喘个人史与神经胶质瘤风险之间呈负相关，这一关联在流行病学文献中得到了相当一致的报道。然而，由于少数研究报告的结果相互矛盾，常规使用抗组胺药与神经胶质瘤风险之间的关系仍存在争议。我们评估了定期使用口服抗组胺药与神经胶质瘤风险之间的关联，并针对一些相关因素（例如免疫球蛋白 E 水平和水痘史）进行了调整。
我们使用哈里斯县病例对照研究的一个子集，其中包括 362 例经病理证实的神经胶质瘤病例和 462 例无癌症对照，使用无条件多变量逻辑回归来评估这种关联。这些模型在整个研究人群中以及根据过敏状态进行分层进行了运行。Cox 回归用于检查抗组胺药的使用是否与所有病例的死亡率以及高级别病例的死亡率相关。
抗组胺药的使用与有过敏/哮喘病史者的神经胶质瘤风险强烈相关（OR：4.19，95%CI：2.06-8.51），但与无过敏/哮喘病史者无关（OR：1.59，95%CI：0.95-2.67）。抗组胺药的使用与病例的生存之间没有显著关联。
目前的研究表明，常规使用抗组胺药可能会增加神经胶质瘤的风险。然而，在得出明确结论之前，还需要进行几项更大的研究。
